Lifeclean Q1’22: First take - Redeye

Redeye saw sales in line with our expectations for the quarter. The gross margin was slightly lower than expected; however, the other Opex was very much in line with expectations. We will make minor adjustments to our cost estimates for the rest of the year but do not expect more than a marginal change to our current Base case value of SEK 10 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/840767/lifeclean-q122-first-take?utm_source=finwire&utm_medium=RSS